These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M Front Immunol; 2022; 13():794684. PubMed ID: 35720386 [TBL] [Abstract][Full Text] [Related]
26. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma. Saito R; Sawada Y; Nakamura M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410 [TBL] [Abstract][Full Text] [Related]
27. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. Simeone E; Ascierto PA J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
29. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064 [TBL] [Abstract][Full Text] [Related]
30. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Kreidieh FY; Tawbi HA Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526 [TBL] [Abstract][Full Text] [Related]
31. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Hermel DJ; Ott PA Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
34. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845 [TBL] [Abstract][Full Text] [Related]
35. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259 [TBL] [Abstract][Full Text] [Related]
36. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346 [TBL] [Abstract][Full Text] [Related]
37. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341 [TBL] [Abstract][Full Text] [Related]
38. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic use of anti-CTLA-4 antibodies. Blank CU; Enk A Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057 [TBL] [Abstract][Full Text] [Related]
40. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]